PRIMARY STUDY
Fatty Acid Amide Hydrolase Inhibitor Treatment in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Adaptive Double-blind, Randomized Controlled Trial
Key Findings: The fatty acid amide hydrolase (FAAH) inhibitor ASP3652 was safe and well-tolerated but was not statistically significant in reducing pain symptoms in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Micturition and voiding frequency improved in the ASP group over placebo.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 226
Study Result: Inconclusive
Research Location(s): Canada, Czech Republic, Germany, Latvia, Lithuania, Poland, United Kingdom, United States
Year of Pub: 2017
Cannabinoids Studied: Fatty Acid Amide Hydrolase (FAAH)
Phytocannabinoid Source: Not Applicable
Dosage: ASP3652 (25, 75, 150, or 300 mg twice daily, or 300 mg once daily)
Route of Administration: Oral (Ingestion)
Citation: Wagenlehner FME, et al. Fatty Acid Amide Hydrolase Inhibitor Treatment in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Adaptive Double-blind, Randomized Controlled Trial. Urology. 2017; 103:191-197. doi: 10.1016/j.urology.2017.02.029
Authors: Wagenlehner FME, van Till JWO, Houbiers JGA, Martina RV, Cerneus DP, Melis JHJM, Majek A, Vjaters E, Urban M, Ramonas H, Shoskes DA, Nickel JC
